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The aim of the study was to analyse outcomes of AVF-RC in predialysis stage in which a
clinical and radiological follow up of its maturation had been done and primary failure had
been  treated.
Material and methods: We  studied 127 RC-AVF in 117 predialysis patients. All cases had
a  preoperative map. The RC-AVF was considered mature if it had a brachial artery ﬂow
≥500  ml/min and a cephalic vein diameter of ≥4 mm. Primary failure was treated radiolo-
gically or surgically depending on the type of lesion. Fifty-eight patients started dialysis at
the time of the study.
Results: In 106 RC-AVF without thrombosis, 72 (68%) were mature and 34 (32%) were imma-
ture. A total of 97% of the immature had at least one lesion, and the most common sitewas  the post-anastomotic vein. Lesions were found in 31% of mature RC-AVF, and 18% of
patients required treatment. Radiological treatment was the most frequent for maturation
ths, primary and secondary patency were 59% and 78%, while afterfailure. After 6 mon12  months they were 48% and 77%, respectively. The 80% of patients started dialysis with a
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distal AVF (76% RC-AVF and 4% ulnar basilic). None of the patients with treated immature
RC-AVF started dialysis with CVC, while 78% of the patients started with said AVF.
Conclusion: Ultrasonography for monitoring maturation provides advantages over clinical
monitoring. With our management of RC-AVF in predialysis, 80% of patients start dialysis
with  an adequate distal AVF.
© 2016 Published by Elsevier Espan˜a, S.L.U. on behalf of Sociedad Espan˜ola de Nefrologı´a.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Importancia  del  seguimiento  y  tratamiento  del  fracaso  de  maduración  en
la  fístula  arteriovenosa  radio-cefálica  en  prediálisis.  Papel  de  la  ecografía
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r  e  s  u  m  e  n
El objetivo del estudio fue analizar las FAV-RC en prediálisis en las que se hizo un
seguimiento clínico y ecográﬁco de la maduración y cuyo fracaso se trató.
Material y métodos: Estudiamos 127 FAV-RC en 117 pacientes prediálisis. Todos disponían
de  un mapa preoperatorio. La FAV-RC era madura si tenía un ﬂujo en la arteria humeral
≥500  ml/min y un diámetro en la vena cefálica ≥4 mm. Se trató el fracaso de madu-
ración según el tipo de lesión. Un total de 58 pacientes iniciaron hemodiálisis durante el
seguimiento.
Resultados: En las 106 FAV-RC funcionantes, 72 (68%) fueron maduras y 34 (32%) inmaduras. El
97%  de las inmaduras presentaron al menos una lesión y la localización más  frecuente fue la
vena postanastomótica. El 31% de las FAV-RC maduras tenían lesiones y en el 18% precisaron
tratamiento. El tratamiento más frecuente del fracaso de maduración fue radiológico. A los
6  meses la permeabilidad primaria y secundaria fue del 59 y del 78%; a los 12 meses del
48  y del 77%, respectivamente. El 80% de los pacientes iniciaron hemodiálisis con una FAV
distal (76% radio-cefálicas y 4% cubitobasílicas). Ningún paciente con una FAV-RC inmadura
tratada lo hizo con CVC y un 78% lo hizo con dicha FAV.
Conclusión: La ecografía en el seguimiento de la maduración aporta ventajas frente al
seguimiento clínico. Con nuestro abordaje del AV en prediálisis conseguimos que el 80%
de  nuestros pacientes inicien hemodiálisis mediante una FAV distal.
© 2016 Publicado por Elsevier Espan˜a, S.L.U. en nombre de Sociedad Espan˜ola de
Nefrologı´a.  Este es un artı´culo Open Access bajo la licencia CC BY-NC-ND (http://
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introduction
 radiocephalic AVF (RC-AVF) is the vascular access (VA) of
hoice for haemodialysis (HD) patients, but it has a high rate of
rimary failure (20%–50%).1,2 Primary failure includes throm-
osis and failure to mature. Maturation is a complex process
hat depends on the interplay of patient-dependent and sur-
ical factors. The fundamental lesion that leads to failure
o mature is stenosis wherein the pathological substrate is
eointimal hyperplasia.3 In predialysis, a diagnosis of matu-
ity tends to be made clinically, although the importance of
ltrasound as a complementary method to have objective
uantitative criteria is being increasingly emphasised. How-
ver, there are not many  systematic ultrasound follow-up
tudies of maturation.4–7 There is effective treatment for fail-
re to mature.8–12 Nonetheless, achieving a RC-AVF suitable
or starting HD remains a signiﬁcant challenge.
For this reason, we studied RC-AVFs placed in predialysis
hat had clinical and ultrasound follow-up of their maturation.
he objectives of this study were to determine the character-
stics of RC-AVFs by ultrasound, also the causes and frequencycreativecommons.org/licenses/by-nc-nd/4.0/).
of failure as well as the treatment for a failure to mature and,
ﬁnally, the percentage that was suitable for use at the start of
HD.
Patients  and  methods
In this retrospective study, we analysed the 127 RC-AVFs that
were placed from January 2009 to March 2013 in 117 consec-
utive patients with G4 and G5 chronic kidney disease (CKD)
without dialysis. By protocol, all patients had recent presur-
gical vascular mapping that consisted of a colour-Doppler
duplex ultrasound scan (Siemens Acuson 150×) and a CO2
venogram (Phillips Ayura) of the upper limb.13 All patients
signed the informed consent form. None of the patients had
nephrotoxicity associated with the limited quantity (3 ml)  of
non-ionic contrast material to as complement to CO2. The
radial, cubital and humeral artery were studied, as well as
the superﬁcial and deep venous system, including the central
veins. The placement of a RC-AVF was not advised if any of the
following conditions were present: if the vessels (radial artery
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and cephalic vein) were <1.6 mm,  if there were irreparable
venous lesions or if there was central ipsilateral stenosis. The
surgical procedure was performed under the same conditions
in all the patients and by the same surgical team. The type of
VA ultimately created by the surgeon was decided according
to the indication of the presurgical mapping and the intraop-
erative ﬁndings.
Monitoring of the maturation of the RC-AVFs was per-
formed in 2 ways:
a) A physical examination, within the ﬁrst 72 h post-surgery,
at the time of ultrasound examination and at each
follow-up visit. This included inspection, palpation and
auscultation of the body and the anastomosis of the RC-
AVF following the previously published protocol.14,15
b) Colour-Doppler duplex ultrasound scan 1–4 months post-
surgery by the same vascular radiology team.
The RC-AVF was considered to be mature if the ﬂow rate in
the humeral artery was ≥500 ml/min and the cephalic vein in
the forearm had a diameter ≥0.4 cm.4 A pseudo-delay of mat-
uration was diagnosed when the above characteristics were
present and the depth of the cephalic vein was >0.5 cm from
the skin surface. Stenosis was considered to be signiﬁcant if
it was >50% of the vascular lumen. The juxta-anastomotic
segment was considered to be the segment between the
anastomosis and the ﬁrst 5 cm of the artery or vein (post-
anastomotic segment).
Maturation  follow-up  protocol  and  therapeutic  approach
Immature RC-AVFs were evaluated using ﬁstulography and
were treated radiologically or surgically depending on the type
of lesion found. Radiological treatment consisted of a per-
cutaneous transluminal angioplasty (PTA) associated or not
associated to permeabilisation of thrombotic venous occlu-
sion using thromboaspiration. Surgical treatment was either
proximal reanastomosis or the creation of a new vascular
access. They were subsequently monitored using serial ultra-
sound until the start of HD.
Mature RC-AVFs with associated lesions (stenosis with or
without thrombotic occlusion) were followed up with ultra-
sound and if at any time there was a decrease in the blood ﬂow,
an increase in the resistive index or both, then the appropriate
treatment, radiological or surgical, was pursued as previously
described.
Mature RC-AVFs without associated lesions were moni-
tored clinically without standardised ultrasound monitoring
until the start of HD. During follow-up an imaging study was
performed only if it was indicated by the clinical examination.
However, in all cases an ultrasound study was performed prior
to the ﬁrst AVF puncture to rule out a complication that would
render its use inadvisable.
The RC-AVF was considered to be suitable if it was the VA
both at the start of HD and throughout the ﬁrst 3 months of
dialysis, without requiring another VA or a central venous
catheter (CVC), even if radiological treatment was required
during this time.;3 6(4):410–417
Statistics
Qualitative variables were expressed in percentages and quan-
titative variables were expressed in means and standard
deviations. The qualitative variables were compared using
the chi-squared test, and the quantitative variables were
compared using comparison of means with Student’s t test
for independent data. We  performed a multivariate logistic
regression study in which the dependent variable was an
immature FC-AVF and some of the variables described in
the literature were included as independent variables (sex,
age, obesity, cardiovascular disease and diabetes mellitus).
Kaplan–Meier survival curves were used to study the primary
and secondary permeability of the 127 FC-AVFs in predial-
ysis. Primary permeability was deﬁned as the time elapsed
from the placement of the AVF to the ﬁrst therapeutic inter-
vention or thrombosis. Secondary permeability was deﬁned
as the time elapsed from the creation of the AVF to its aban-
donment due to irreparable dysfunction, or to the start of HD
or end of the follow-up period in patients who  did not start
HD during that time. Finally, we prepared a ROC curve to pre-
dict the required arterial ﬂow rate that would determine the
clinical sign of non-collapsible hyperpulsatility in immature
RC-AVFs with signiﬁcant post-anastomotic stenosis. A p value
<0.05 was considered to be statistically signiﬁcant. The data
were analysed using SPSS version 20.0.
Results
Of the 127 RC-AVFs, 21 (16%) had thrombosis in the ﬁrst 72 h.
In the remaining 106 RC-AVFs, after the ultrasound study, 72
(68%) were mature and 34 (32%) were immature.
Mean patient age was 68 ± 13 years, 38% were diabetic and
33% had clinical evidence of cardiovascular disease (ischaemic
cardiomyopathy, ischaemic cerebrovascular accident, inter-
mittent claudication or peripheral ischaemic lesions). clinical
manifestation of cardiovascular disease was present in 47% of
patients with an immature RC-AVF and 26% of patients with
a mature RC-AVF (p < 0.035) (Table 1). In the logistic regression
study the only variable of those studied that was associated
with an immature RC-AVF was cardiovascular disease with an
OR of 2.6 (95% CI: 1.1–6.1; p < 0.03).
Ultrasound  characteristics  of  functioning  radiocephalic
arteriovenous  ﬁstulas
Mean ﬂow rate in the humeral artery was 805 ± 479 ml/min.
Flow rate exceeded one litre per minute in 27% of cases and
1.5 l/min in 11% of cases.
In mature RC-AVFs, mean ﬂow rate in the humeral artery
was 1014 ± 434 ml/min and internal diameters in the differ-
ent thirds of the cephalic vein, from distal to proximal, were
5 ± 1.6; 5.4 ± 1.1 and 5.5 ± 0.9 mm,  respectively (Fig. 1). We
found no lesions in 69% of RC-AVFs, at least one lesion (steno-
sis with or without thrombotic occlusion) in 31% of them, and
of these, we found more  than one lesion in 18%. In 28% of
cases, the lesion was post-anastomotic venous stenosis (in
10% it was signiﬁcant and in 18% it was not signiﬁcant), and in
8% of cases, it was located in the proximal vein (1% signiﬁcant,
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Table 1 – Demographic and clinical characteristics of the population. Comparison of these characteristics between
mature and immature RC-AVFs.
Variable Total population (n = 117) Immature RC-AVF (n = 34) Mature RC-AVF (n = 72) p
Age (mean [SD]) (years) 68 (13) 69 (14) 68 (12) NS
Men/women (n) 65/52 18/15 39/31 NS
Left/right RC-AVFs 102/25
Diabetes mellitus, n (%) 44 (38) 17 (50) 23 (32) NS
Cardiovascular disease n (%) 38 (33) 16 (47) 19 (26) <0.035
Obesity (BMI > 33), n (%) 30 (26) 9 (26) 19 (26) NS
CKD aetiology, %
Diabetic 22 37 15 NS
Vascular 21 15 24
Glomerular 20 24 21
Polycystitis 11 9 10
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% not signiﬁcant and 4% occlusion). Among mature RC-AVFs,
7% had a maturation pseudo-delay. We found an aneurysm
ithout stenosis in 6%.
In immature RC-AVFs, mean ﬂow rate in the humeral artery
as 362 ± 164 ml/min and internal diameters in the differ-
nt thirds of the cephalic vein, from distal to proximal, were
.6 ± 1.6; 4 ± 1.6 and 4.4 ± 1.7 mm,  respectively (Fig. 1). In 97%
f cases, signiﬁcant stenosis was found, and of these cases,
2% had more  than one lesion. It was located in the post-
nastomotic vein in 76% of cases, in the proximal vein in
2% of cases (of these, half were thrombotic occlusion), in the
nastomosis in 6% of cases and in the artery in 18% of cases
11% juxta-anastomotic and 7% diffuse). Only 3% of immature
C-AVFs did not have underlying lesions.
Therefore, the most common cause of failure to mature
as signiﬁcant stenosis in the post-anastomotic vein. This
esion often presents a non-collapsible hyperpulsatility on
aising the arm. In our case, this sign was present in 60% of
mmature RC-AVFs with signiﬁcant post-anastomotic venous
tenosis. We  found a signiﬁcant difference (p < 0.049) in the
ow rate of the humeral artery between those with the sign
ﬂow rate 443 ± 182 ml/min) and those without it (ﬂow rate
07 ± 114 ml/min). In our population, hyperpulsatility as a sign
f signiﬁcant post-anastomotic venous stenosis in immature
C-AVFs was present when the ﬂow rate was ≥385 ml/min
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ig. 1 – Ultrasound characteristics of mature and immature RC-A
ifferences in ﬂow rate (p < 0.000). B) Diameters of the cephalic ve
igniﬁcant difference in diameters (p < 0.000).5 30
(sensitivity: 73% and speciﬁcity: 90%) (AUC: 0.76; 95% CI:
0.56–0.96; p < 0.03).
Treatment  of  radiocephalic  arteriovenous  ﬁstulas
Of the 127 RC-AVFs studied, 58 (46%) received some type of
treatment in predialysis. The causes were: 11% post-surgical
thrombosis, 24% failure to mature, 6% lesions that progressed
in mature RC-AVFs and 5% a maturation pseudo-delay. The
type of treatment was: in 20 (16%) a new VA (12 contralateral
RC-AVFs, 4 humeral–cephalic RC-AVFs, 2 cubital–basilic RC-
AVFs, one humeral–basilic RC-AVF and one humeral–axillary
graft), in 24 (19%) radiological, in 8 (6%) proximal reanastomo-
sis, and in 6 (5%) vein superﬁcialisation.
Among mature RC-AVFs, 18% required treatment. In imma-
ture RC-AVFs, 88% require treatment, and only 12% were not
treated (one case due to the absence of an underlying lesion,
2 cases due death and another case due to patient’s refusal).
Table 2 shows the treatment performed in each type of
AVF (mature with or without lesions, and immature with or
without lesions). Among mature RC-AVFs without lesions,
10% required surgical treatment (cephalic vein superﬁcialisa-
tion). Regarding mature RC-AVFs with associated lesions, 36%
required treatment: surgical in 37.5% of cases and radiological
in 62.5% of cases. Finally, in the case of immature RC-AVFs,
4.4
3.6
5.5
5.4
5
4
Cephalic vein diameter
(mm)
Immature
Mature
VFs. A) Flow rate in the humeral artery. Signiﬁcant
in in the forearm in its distal, medial and proximal third.
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Table 2 – Type of treatment according to type of RC-AVF.
Type of AVF With lesion Type of treatment
Mature AVF (n = 72) Without lesion
(n = 50)
5  superﬁcialisations
With lesion
(n = 22)
1  superﬁcialisation
1  reanastomosis
1  new VA
5 PTAs
Immature AVF
(n = 34)
Without lesion
(n = 1)
No
With lesion
(n = 33)
19  PTAs
5  reanastomosis
6  new VAs
Site of PTA (n=28)
22%
(n=6)
64%
(n=18)
14%
(n=4)
Location of the lesions that had undergone angioplasty (n=28)3 no
56% were treated radiologically, 32% were treated surgically
and 12% received no treatment for the above-mentioned rea-
sons. Therefore, the most common treatment in immature
and mature RC-AVFs with lesions was radiological.
A total of 28 PTAs were performed in 24 RC-AVFs (19 imma-
ture and 5 mature with lesions that progressed). A PTA of one
lesion was performed in 20 patients, and a PTA of 2 lesions was
performed in the same procedure in 4 patients. In 3 cases, in
addition to a PTA, the vein was repermeabilised owing to asso-
ciated thrombotic occlusion. Fig. 2 shows the location of the
lesions treated using a PTA.
Post-anastomotic venous stenosis was treated with a PTA
in 19 cases (68%), a new VA in 5 cases (18%) and proximal
reanastomosis in 4 cases (14%).
Clinical  course  of  the  arteriovenous  ﬁstulas  treated
Of the patients who  were treated radiologically, 17 started
HD during the study, and in these patients the mean num-
ber of predialysis PTAs was 1.2 ± 0.4. One PTA was required
in 77% and 2 PTAs were required in 23% prior to the start of
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Fig. 3 – Primary and secondaFig. 2 – Radiological treatment of RC-AVFs in predialysis.
HD. Mean time between the ﬁrst PTA and the start of HD was
6.4 ± 8 months (1–32 months). In 94% of RC-AVFs treated radio-
logically, this AVF was the VA at the start of HD, and in 6%,
another type of AVF had to be placed (one patient required a
humeral–axillary graft since that patient had previously had a
contralateral RC-AVF placed and it too had failed).
In the subgroup of patients with signiﬁcant post-
anastomotic venous stenosis the AVF worked at the
commencement of HD in 93% of those treated with a PTA (14 of
15) and 100% (2 of 2) who underwent proximal reanastomosis.
The primary and secondary permeability curves of all the
RC-AVFs in predialysis are shown in Fig. 3. Primary and sec-
ondary permeability were 59% and 78% at 6 months, 48% and
77% at 12 months, and 43% and 75% at 24 months, respectively.
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haracteristics  of  the  vascular  access  at  the  start  of
aemodialysis
f the 58 patients who started HD at the time of the
tudy, 76% did so with a RC-AVF, 10% with another AVF (5%
umeral–cephalic, 4% cubital–basilic and 1% humeral–axillary
raft) and 14% with a CVC. Mean time between surgery and the
tart of HD was 12.7 ± 10.7 months.
Of the 44 RC-AVFs that were suitable at the start of HD, 43%
f them were treated in predialysis (36% radiologically and 7%
urgically).
Fig. 4 schematically represents the type of VA used to start
D according to RC-AVF, whether it was immature, immature
peciﬁcally treated in predialysis or mature. Of the 58 patients
ho  started HD, 23 had an immature RC-AVF and 35 had a
ature AVF with or without lesions. Of the 23 patients with
n immature RC-AVF, 5 (22%) required a CVC since the start
f HD was unexpected and, as a result, there was not time
Immature RC-AVF (n=23)
Immature RC-AVF treated in predialysis (n=18)
Mature RC-AVF +/– lesions (n=35)
VA at the start of HD
22% with CVC
61% RC-AVF
17% Other AVF
0% with CVC
78% RC-AVF
100% RC-AVF
RC-AVF suitable
at the start of dialysis
22% Other AVF
ig. 4 – VA at the start of dialysis in relation to type of
C-AVF in predialysis.
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ig. 5 – Difference in time between surgery and the start of
aemodialysis between the patients who  started it with
VC and without CVC.(4):410–417 415
enough to perform a treatment in predialysis. One out of the 5
patients with immature RC-AVF was not treated owing to the
patient’s refusal and the AVF was irreparable at the time of
the start of dialysis. The 4 remaining patients received a treat-
ment during the ﬁrst week of dialysis session: one case with a
PTA, 2 cases with proximal reanastomosis and one case with
a contralateral RC-AVF. In patients with an immature RC-AVF
speciﬁcally treated in predialysis (18 patients), none of them
required a CVC and 78% did so with this RC-AVF. Finally, all
the patients with a mature RC-AVF with or without associated
lesions started HD using their RC-AVF.
The patients who started HD using a CVC (n = 8) and those
who did so with an AVF (n = 50), had no signiﬁcant differences
in relation to age, sex, diabetes mellitus, cardiovascular dis-
ease, obesity or CKD aetiology. The only difference observed
was the time elapsed between surgery and the start of HD (5
months versus 13 months, p < 0.04) (Fig. 5).
Discussion
Consistent with the literature, 43% of our RC-AVFs had a
primary failure that required a treatment in predialysis to
avoid the use of CVC at the start of HD.1,2 In 16%, thrombosis
occurred in the ﬁrst 72 h, and 32% of non-thrombosed RC-AVFs
had a failure to mature.
Maturation is a very complex process that makes a RC-AVF
becomes suitable for HD. It starts at when the anastomo-
sis is created and is followed by vascular remodelling that
includes an increase in the diameter and arterial and venous
blood ﬂow, as well as a thickening of the venous wall that
will allow repeated venipuncture and a sufﬁcient ﬂow rate
for HD.16,17 The complexity of this process reﬂects the fact
that it is a result of the interplay of multiple factors. Some
are patient-dependent factors that will determine the capac-
ity for vascular remodelling. Others are surgical factors that
will create the intra-FAV shear pressure required for vascular
remodelling.18
Presurgical factors reported to be associated with a fail-
ure to mature include female sex, obesity, diabetes, age
and cardiovascular disease.12,18,19 In our case, the only one
of the above variables associated with a failure to mature
was clinically manifestation of cardiovascular disease. The
many  traditional and non-traditional factors (oxidative stress,
inﬂammation, calcium and phosphorus metabolism, nutri-
tion, and endothelial dysfunction) associated with CKD that
determine a greater cardiovascular risk in these patients may
contribute to a VA’s failure to mature.20 CKD is known to
accelerate venous neointimal hyperplasia in animal models.21
Moreover, 83% of patients with advanced CKD have venous
neointimal hyperplasia at the time of surgery.3 Finally, the
potential contribution to a failure to mature of the abnor-
mal  capacity for arterial and venous vasodilatation in patients
with CKD should be taken into consideration.22,23
Currently, we  do not have vascular anatomical and func-
tional able to deﬁne the risk for a failure to mature of a
ﬁstula7; however presurgical mapping in all patients, as well
as a good surgical technique, may contribute to obviate the
negative effect of the above-mentioned factors on a failure
to mature.24–27 Multiple studies have demonstrated similar
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results in these populations at risk when preoperative ultra-
sound is used.28–33
It is known that systematic preoperative ultrasound eval-
uation increases the percentage of RC-AVFs performed,
although it also increases the number of immature RC-AVFs.33
However, if a protocol is applied for early and effective treat-
ment of a failure to mature, the ﬁnal result will be an increase
in the number RC-AVFs that ready to be use at the start of HD.
Our protocol for approaching a VA in predialysis is an example
of this concept, such that 78% of the patients with an imma-
ture RC-AVF that is treated in predialysis will start HD with
this AVF and none with a CVC.
In immature RC-AVFs, we  found an underlying lesion in
almost 100% of cases. As in other series, the most com-
mon  location of the lesion was the post-anastomotic vein.8
There were different reasons to explain this, but essen-
tially, the conﬁguration of the AVF itself is contributing factor
due the abnormal stress generated shear pressure exerted
on the endothelium and also the potential injury due to
surgical manipulation. Both of these factors would stimu-
late neointimal hyperplasia and vasoconstriction resulting in
stenosis.16,34–38 In our case, this lesion was treated radiolo-
gically in the majority of cases with a good outcome and
required re-interventiont in a relatively low percentage of
cases (20%). Currently, the superiority of surgical vs radiologi-
cal treatment in this type of lesion has not been established.39
Availability at each centre will determine the type of treat-
ment used. In our department, the most common treatment is
radiological; surgical treatment is reserved for certain lesions
that would not beneﬁt from PTA (long or multiple lesions).
Therefore, in our case, we cannot compare the outcomes of
the two treatments. Another fact of interest supporting ultra-
sound follow-up in immature RC-AVFs is that only 60% of
cases with signiﬁcant post-anastomotic stenosis had non-
collapsible hyperpulsatility, and so a clinical examination
would have a limitation their diagnosis.14
It should be noted that mature RC-AVFs had lesions in
31% of cases and that 18% of cases will progress and will
require treatment in predialysis. This highlight the fact that
ultrasound follow-up of the maturation offers advantages
over exclusively clinical follow-up; this had already been pub-
lished in other series but with a lower number of RC-AVFs.5,6
Moreover, ultrasound was essential for the diagnosis of a mat-
uration pseudo-delay (which affected 17% of our mature AVFs).
Finally, it should be noted that a high percentage of our AVFs
had high ﬂow rates, which alert about the potential deleterious
cardiological effect in the mid- to long term.40,41
In our patients the most common type of treatment of fail-
ure to mature was radiological. The difference between the
primary and secondary permeability curves, which is very
similar to those previously published,8,12 illustrate the efﬁcacy
of the treatment of failure to mature in our patients. Over-
all, 94% of immature RC-AVFs treated radiologically will be
suitable at the start of HD.
Finally, the most determining factor for avoiding a CVC was
placement of RC-AVF with enough time in advance sp the diag-
nose and treatment of primary failure before can be made
before commencenment of HD. The time to place a VA in pre-
dialysis is very difﬁcult to determine. In our case, it seems that
VA should be placed at least 6–12 months prior to the start of;3 6(4):410–417
HD, which would be in line with the recommendations of the
different guidelines.42–44
In summary, ultrasound was very useful in the study of
maturation of VA in predialysis since it allowed us: A) To deter-
mine the patient’s vascular status regardless of his or her
potential comorbidities. B) To diagnose an immature AVF and
its potential causes and guide its treatment. C) To diagnose,
in mature AVFs, potential associated lesions, which may ini-
tially have no functional repercussions but may progress and
require treatment. D) To diagnose a maturation pseudo-delay.
E) To quantify the vascular ﬂow rate. F) To diagnose in some
cases lesions that did not have clinical expressivity. There-
fore, all the above contingencies show that ultrasound in the
follow-up of maturation offers advantages over exclusively
clinical follow-up, such that they should complement each
other.
In conclusion, with our approach to the VA in predialysis
we have achieved that 80% of our patients were able to start HD
using a distal AVF (76% radiocephalic and 4% cubital–basilic),
potential complications of more  proximal VA have been pre-
vented and therefore we have saved venous resources that
may be vital for our patients’ future.
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